Genomic instability of ovarian cancer (OvCa) cells and the resulting frequent loss or reduction of HLA expression and function facilitate immune avoidance of this aggressive cancer. The goal of this Project is to develop an effective mode of immunotherapy capable of targeting both MHC-positive and MHC-negative variants of OvCa and counteracting local immune suppression, known to contribute to poor prognosis in OvCa patients. We observed that type-1-polarized DCs (?DC1s), a novel type of DCs developed by our group, effectively cross-present OvCa-related antigens and induce high numbers of MHC class l-restricted CTLs capable of recognizing defined OvCa-related antigenic epitopes. However ?DC1-induced CTLs also express elevated levels of NK receptors, NKG2D- and DNAM1. Such "NK cell-like" (n)CTLs recognize OvCa cells in both MHC class l-restricted- and MHC class l-unrestricted fashion. IFN? produced by ?DC1-activated nCTLs has a strong positive impact on OvCa microenvironment, suppressing the chemokines that attract undesirable Treg cells and MDSCs and enhancing the producfion of the chemokines that attract additional effector cells. Based on these preliminary data, we hypothesize that autologous tumor-loaded ?DCIs used both as vaccines and as ex-vivo inducers of OvCa-specific CTLs for adoptive T cell transfer in OvCa can be useful in the immunotherapy of patients treated with primary chemotherapy (which may sensitize tumor cells for the NKG2D- and DNAM-1-mediated recognition). We will test the hypothesis that local adoptive transfer of ex-vivo-sensitized (n)CTLs will amplify the effects of systemic vaccination against OvCa, by promoting direct elimination of residual tumor cells and the attraction of additional (vaccination induced) T cells.
In Specific Aim 1, we will evaluate the mechanisms involved in the inducfion of OvCa-specific NKG2D{high}/DNAM-1{high} (n)CTLs by ?DCIs and the mechanisms of their TCR-dependent and TCR-independent recognifion and killing of OvCa cells.
In Specific Aim 2, we will evaluate the regulafion of the NK cell-type receptors ligands (MICA/B, ULBP1-6, PVR/CD155 and Necfin-2/CD112) on OvCa cells by chemotherapy, CTL/NK-produced cytokines and addifional clinically-applicable biologic agents, and will evaluate the potenfial for additional sensitizafion of OvCa cells for (n)CTL-mediated killing.
In Specific Aim 3, we will evaluate in phase I clinical trial (24 high-risk pafients with advanced primary OvCa) the feasibility and safety of combined immunotherapy of advanced OvCa involving vaccination with autologous tumorloaded ?DCIs and intraperitoneal adoptive transfer of increasing numbers ex-vivo-induced OvCa-specific (n)CTLs, in the context of systemic and intraperitoneal chemotherapy.

Public Health Relevance

We plan to develop a new immunotherapy of ovarian cancer, combining a new highly-potent autologous dendritic cells vaccine (aDC1s) with the local infusion of ex-vivo aDC1-induced effector CD8+ T cells (CTLs) able of recognizing tumor cells both in a classical (TCR-dependent) and TCR-independent manner. We anticipate that such treatment will promote destruction of residual tumor cells in patients with advanced ovarian cancer treated with chemotherapy, independently on their ability to mutate and evade classical forms of immune recognition, preventing or delaying tumor recurrence.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA159981-02
Application #
8754346
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
2
Fiscal Year
2014
Total Cost
$441,496
Indirect Cost
$145,446
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Gil, Margaret; Komorowski, Marcin P; Seshadri, Mukund et al. (2014) CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells. J Immunol 193:5327-37
Eng, Kevin H; Ruggeri, Christina (2014) Connecting prognostic ligand receptor signaling loops in advanced ovarian cancer. PLoS One 9:e107193
Liao, Jianqun; Qian, Feng; Tchabo, Nana et al. (2014) Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism. PLoS One 9:e84941
Suryawanshi, Swati; Huang, Xin; Elishaev, Esther et al. (2014) Complement pathway is frequently altered in endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res 20:6163-74
Matsuzaki, Junko; Tsuji, Takemasa; Luescher, Immanuel et al. (2014) Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells. Cancer Immunol Res 2:341-50
Daudi, Sayeema; Eng, Kevin H; Mhawech-Fauceglia, Paulette et al. (2014) Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer. PLoS One 9:e104099